Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging.

Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer, yet early, precise, and noninvasive detection continues to pose a considerable clinical challenge. Glypican-3 (GPC3), a membrane-bound proteoglycan, is markedly overexpressed in most HCC cases, while exhibiting low expression in normal and hepatitis-affected liver tissues. Given its crucial role in malignant transformation and tumor progression, GPC3 emerges as a compelling target for imaging.

Synthesis and preclinical evaluation of [F]AlF-NOTA-Asp-PEG-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor.

Purpose: Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [F]AlF-NOTA-Asp-PEG-JR11, and compare its preclinical performance with the previously reported antagonist, [F]AlF-NOTA-JR11, and the agonist [Ga]Ga-DOTA-TATE.

Methods: [F]AlF-NOTA-Asp-PEG-JR11 was synthesized via a one-step radiolabeling process involving [F]AlF chelation.

Synthesis and Preclinical Evaluation of [F]AlF-NOTA-Asp-PEG-Folate as a Novel Folate-Receptor-Targeted Tracer for PET Imaging.

Recently, the folate receptor (FR) has become an exciting target for the diagnosis of FR-positive malignancies. Nevertheless, suboptimal in vivo pharmacokinetic properties, particularly high uptake in the renal and hepatobiliary systems, are important limiting factors for the clinical translation of most FR-based radiotracers. In this study, we developed a novel F-labeled FR-targeted positron emission tomography (PET) tracer [F]AlF-NOTA-Asp-PEG-Folate modified with a hydrophilic linker (-Asp-PEG) to optimize its pharmacokinetic properties and conducted a comprehensive preclinical assessment.

Synthesis and preclinical evaluation of a novel probe [F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor.

Glypican-3 (GPC3) is markedly overexpressed in hepatocellular carcinoma (HCC) and not expressed in normal liver tissues. In this study, a novel peptide PET imaging agent ([F]AlF-NOTA-IPB-GPC3P) was developed to target GPC3 expressed in tumors. The overall radiochemical yield of [F]AlF-NOTA-IPB-GPC3P was 10-15 %, and its lipophilicity, expressed as the logD value at a pH of 7.

Synthesis and preclinical evaluation of a novel molecular probe [F]AlF-NOTA-PEG-Asp-PDL1P for PET imaging of PD-L1 positive tumor.

Immunotherapy has brought great benefits to cancer patients, but only some patients benefit from it. Noninvasive, real-time and dynamic monitoring of the effectiveness of immunotherapy through PET imaging may provide assistance for the treatment plan of immunotherapy. In this study, we designed and synthesized a new targeted PD-L1 peptide NOTA-PEG-Asp-PDL1P, which was labeled with nuclide F to obtain a new imaging agent [F]AlF-NOTA-PEG-Asp-PDL1P.

Polyethylene glycol-coated ultrasmall superparamagnetic iron oxide nanoparticles-coupled sialyl Lewis X nanotheranostic platform for nasopharyngeal carcinoma imaging and photothermal therapy.

Background: Nasopharyngeal carcinoma (NPC) is a type of head and neck malignant tumor with a high incidence in specific regional distribution, and its traditional therapies face some challenges. It has become an urgent need to seek new therapeutic strategies without or with low toxicity and side effects. At present, more and more researchers has been attracting attention by nanotheranostic platform.